Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Norhammar

Showing results (31-40 of 106) with videos related to

Pageof 11
Sort By:
Heart (British Cardiac Society)|June 3, 2015
Risk factors, treatment and prognosis in men and women with heart failure with and without diabetesIsabelle Johansson, Ulf Dahlström, Magnus Edner, et al.
Diabetologia|May 19, 2016
Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006-2013Anna Norhammar, Johan Bodegård, Thomas Nyström, et al.
Diabetes Research and Clinical Practice|January 6, 2017
Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemiaThomas Nyström, Johan Bodegard, David Nathanson, et al.
Diabetes, Obesity & Metabolism|January 25, 2017
Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetesThomas Nyström, Johan Bodegard, David Nathanson, et al.
Diabetes, Obesity & Metabolism|June 17, 2026
Cardiovascular Outcomes in a SELECT-Like Obesity Cohort: Real-World Insights From the Swedish AROS DatabaseViveca Ritsinger, Josefine Fagerström, Håkan Nero, et al.
Cardiovascular Diabetology|November 25, 2021
Impaired fasting glucose: a risk factor for atrial fibrillation and heart failureViktor Lind, Niklas Hammar, Pia Lundman, et al.
Journal of the American College of Cardiology|February 21, 2004
Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularizationAnna Norhammar, Klas Malmberg, Erik Diderholm, et al.
Diabetes Research and Clinical Practice|June 23, 2016
Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortalityJan W Eriksson, Johan Bodegard, David Nathanson, et al.
Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society|August 19, 2015
Improved glycemic control due to sitagliptin is not related to cortisol or the surrogate marker IGFBP-1 for hepatic insulin sensitivityLisa Arnetz, Camilla Hage, Neda Rajamand Ekberg, et al.
Lancet (London, England)|July 2, 2002
Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective studyAnna Norhammar, Ake Tenerz, Göran Nilsson, et al.
Pageof 11

Showing results (31-40 of 106) with videos related to

Sort By:
Pageof 11
Heart (British Cardiac Society)|June 3, 2015
Risk factors, treatment and prognosis in men and women with heart failure with and without diabetesIsabelle Johansson, Ulf Dahlström, Magnus Edner, et al.
Diabetologia|May 19, 2016
Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006-2013Anna Norhammar, Johan Bodegård, Thomas Nyström, et al.
Diabetes Research and Clinical Practice|January 6, 2017
Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemiaThomas Nyström, Johan Bodegard, David Nathanson, et al.
Diabetes, Obesity & Metabolism|January 25, 2017
Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetesThomas Nyström, Johan Bodegard, David Nathanson, et al.
Diabetes, Obesity & Metabolism|June 17, 2026
Cardiovascular Outcomes in a SELECT-Like Obesity Cohort: Real-World Insights From the Swedish AROS DatabaseViveca Ritsinger, Josefine Fagerström, Håkan Nero, et al.
Cardiovascular Diabetology|November 25, 2021
Impaired fasting glucose: a risk factor for atrial fibrillation and heart failureViktor Lind, Niklas Hammar, Pia Lundman, et al.
Journal of the American College of Cardiology|February 21, 2004
Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularizationAnna Norhammar, Klas Malmberg, Erik Diderholm, et al.
Diabetes Research and Clinical Practice|June 23, 2016
Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortalityJan W Eriksson, Johan Bodegard, David Nathanson, et al.
Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society|August 19, 2015
Improved glycemic control due to sitagliptin is not related to cortisol or the surrogate marker IGFBP-1 for hepatic insulin sensitivityLisa Arnetz, Camilla Hage, Neda Rajamand Ekberg, et al.
Lancet (London, England)|July 2, 2002
Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective studyAnna Norhammar, Ake Tenerz, Göran Nilsson, et al.
Pageof 11